MedTrace Logo

Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study

NCT05493059 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-08-09

No results posted yet for this study

Summary

Miltefosine is the only oral treatment currently available for Cutaneous Leishmaniasis.

Despite several reports of good efficiency in other countries of South America, miltefosine remains limited to a compassionate use in France. The objective of this study is to collect data regarding the efficacy, safety and acceptability of miltefosine in patients treated in French Guiana since 2017.

Conditions

  • Cutaneous Leishmaniases
  • Treatment Adherence
  • Primary Health Care
  • Drug Evaluation

Interventions

OTHER

Data collection

o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)

OTHER

Questionnaires

o Administration of two standardized questionnaires by telephone in prospective: * Dermatology Life Quality Index (DLQI) * Treatment Satisfaction Questionnaire for Medication (TSQM)

Sponsors & Collaborators

  • Centre Hospitalier de Cayenne

    lead OTHER

Principal Investigators

  • Romain BLAIZOT · Centre Hospitalier de Cayenne, Dermatology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2022-08-08
Completion
2022-10-08

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493059 on ClinicalTrials.gov